Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?
- PMID: 11312237
- PMCID: PMC1120143
- DOI: 10.1136/bmj.322.7292.989
Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?
References
-
- Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114. - PubMed
-
- Department of Health and Human Services. Food and Drug Administration. International conference on harmonisation; guidance on statistical principles for clinical trials. Federal Register. 1998;63:49583–49598. . (Docket no 97D-0174.) - PubMed
-
- Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46. - PubMed
-
- Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Control Clin Trials. 1999;20:16–39. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources